Pathogen inactivation of blood components

Transfusion Alternatives in Transfusion Medicine

Volumn 10, Issue 3, 2008, Pages 139-146

  Prowse, Chris ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

Bacteria; Blood transfusion; Component; Inactivation; Pathogen; Virus

Indexed keywords

AMOTOSALEN; METHYLENE BLUE; RIBOFLAVIN;

APHERESIS; ARTICLE; BACTERIUM CONTAMINATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD COMPONENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG STRUCTURE; ERYTHROCYTE TRANSFUSION; HUMAN; INFECTION CONTROL; INFECTION RISK; LEUKAPHERESIS; PATHOGENICITY; PHOTOACTIVATION; PLASMA TRANSFUSION; PRIORITY JOURNAL; SCREENING TEST; TOXICOLOGY; TRANSFUSION RELATED ACUTE LUNG INJURY; VIRUS INACTIVATION;

EID: 65249112222     PISSN: 12959022     EISSN: 1778428X     Source Type: Journal    
DOI: 10.1111/j.1778-428X.2008.00113.x     Document Type: Article

References (46)

1. Bryant BJ, Klein HG. Pathogen inactivation: The definitive safeguard for the blood supply. Arch Pathol Lab Med 2007; 131: 719-33.
2. Prowse C. Kill and cure. The hope and reality of virus inactivation. Vox Sang 1994; 67(Suppl. 3): 191-6.
3. Prowse C. Zero tolerance. Transfusion 2007; 47: 1106-9.
4. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma. Blood 1992; 79: 826-31.
5. Burnouf T, Goubran HA, Radosevich M, et al. A process for solvent/ detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. Transfusion 2006; 46: 2100-8.
6. Burnouf T, Radosevich M, El-Ekiaby M, et al. Nanofiltration of single plasma donations: Feasibility study. Vox Sang 2003; 84: 111-19.
7. Burnouf-Radosevich M, Burnouf T, Huart JJ. A pasteurized therapeutic plasma. Infusionsther Transfusionsmed 1992; 19: 91-4.
8. Lambrecht B, Mohr H, Knüver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991; 60: 207-13.
9. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37: 423-35.
10. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17.
11. Mohr H, Redecker-Klein A. Inactivation of pathogens in platelet concentrates by using a two-step procedure. Vox Sang 2003; 84: 96-104.
12. Lazo A, Tassello J, Jayarama V, et al. Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry. Vox Sang 2002; 83: 313-23.
13. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: A Phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45: 1739-49.
14. Wagner SJ, Skripchenko A, Cincotta L, Thompson-Montgomery D, Awatefe H. Use of a flexible thiopyrylium photosensitizer and competitive inhibitor for pathogen reduction of viruses and bacteria with retention of red cell storage properties. Transfusion 2005; 45: 752-60.
15. Skripchenko A, Wagner SJ, Thompson-Montgomery D, Awatefe H. Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties. Transfusion 2006; 46: 213-19.
16. Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004; 126: 139-52.
17. Pehta JC. Clinical studies with solvent-detergent-treated products. Transfus Med Rev 1996; 10: 303-11.
18. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39: 1227-34.
19. Coignard BP, Colquhoun SD, Nguyen GT, et al. Intra-operative deaths in liver transplant recipients associated with the use of solvent/detergent plasma [abstract]. Hepatology 2002; 36: A209.
20. Ozier Y, Rieux C. Liver transplantation, solvent-detergent-treated plasma and antifibrinolytics. Anesth Analg 2003; 96: 1231-2.
21. Williamson LM, Llewelyn CA. Efficacy of SD-treated plasma during liver transplantation (reply). Transfusion 2000; 40: 886-8.
22. Williamson L, Cardigan R, Prowse C. Methylene blue-treated fresh-frozen plasma: What is its contribution to blood safety? Transfusion 2003; 43: 1322-9.
23. Alvarez-Larren A, Del Rio J, Ramirez C, et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004; 86: 246-51.
24. de Alarcon P, Benjamin R, Dugdale M, et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005; 45: 1362-72.
25. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107: 3753-9.
26. Mintz PD, Neff A, MacKenzie M, et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006; 46: 1693-704.
27. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41.
28. Goodrich RP, Li J, Pieters H, et al. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90: 279-85.
29. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood 2003; 101: 2426-33.
30. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood 2004; 104: 1534-41.
31. AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: A Phase I clinical study. Transfusion 2002; 42: 146-52.
32. Rios JA, Hambleton J, Viele M, et al. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 2006; 46: 1778-86.
33. Heger A, Romisch J, Svae TE. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas)(R) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apheresis Sci 2006; 35: 223-33.
34. Ciaravino V, McCullough T, Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion 2003; 43: 1481-92.
35. Chapman JR, Moore K, Butterworth BE. Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies. Transfusion 2003; 43: 1386-93.
36. Ciaravino V, McCullough T, Cimino G, Sullivan T. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang 2003; 85: 171-82.
37. Lin L, Conlan MG, Tessman J, Cimino G, Porter S. Amotosalen interactions with platelet and plasma components: Absence of neoantigen formation after photochemical treatment. Transfusion 2005; 45: 1610-20.
38. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-85.
39. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent treated pooled plasma. Transfusion 2001; 41: 1203-6.
40. Fast LD, Semple JW, DiLeone G, et al. Inhibition of xenogeneic GVHD by PEN110 treatment of donor human PBMNCs. Transfusion 2004; 44: 282-5.
41. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93: 3140-7.
42. Jackson BR, AuBuchon JP, Birkmeyer JD. Update of cost-effectiveness analysis for solvent-detergent treated plasma. JAMA 1999; 282: 329-30.
43. Sachs UJ, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 2005; 45: 1628-31.
44. Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003; 85: 88-95.
45. Janssen MP, van der Poel CL, Buskens E, et al. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006; 46: 956-65.
46. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: Making decisions about new technologies - preliminary report of a consensus conference. Vox Sang 2007; 93: 179-82.